Company / Operating Cash Flow per Share
Viking Therapeutics, Inc. Operating Cash Flow per Share History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Operating Cash Flow per Share
-$2.50
FY2025
5-year range
-$2.50 / -$0.30
FY2021-FY2025
Trend
-184.8%
vs FY2024
Sector context
#160 of 212
Health Care
What the data says
Viking Therapeutics, Inc.'s operating cash flow per share of $-2.50 is lower than 75% of companies in the Health Care sector (FY2025). Operating Cash Flow per Share has fluctuated over the past 10 years, ranging from $-2.50 in FY2025 to $-0.26 in FY2019.
Based on SEC 10-K filings.
-2.50 in FY2025.
Declined from $-0.61 to $-2.50 over the past 2 years.
Health Care sector context is included.
Operating Cash Flow per Share over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
+83.0% above sector average
Key checks
Key Insights
- In FY2025, operating cash flow per share decreased 184.8% year-over-year.
- Ranks #160 out of 212 companies in the Health Care sector.
- Peak operating cash flow per share was recorded in FY2019.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Operating Cash Flow per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$2.50 | -184.8% |
| FY2024 | -$0.88 | -44.2% |
| FY2023 | -$0.61 | +0.0% |
| FY2022 | -$0.61 | -104.5% |
| FY2021 | -$0.30 | +13.0% |
| FY2020 | -$0.34 | -30.8% |
| FY2019 | -$0.26 | +36.6% |
| FY2018 | -$0.41 | +41.9% |
| FY2017 | -$0.71 | +21.4% |
| FY2016 | -$0.90 | -239.9% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026